Barings LLC continued to hold its position in China Biologic Products, Inc. (NASDAQ:CBPO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 117,080 shares of the biopharmaceutical company’s stock at the close of the second quarter. Barings LLC owned 0.43% of China Biologic Products worth $11,723,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. AHL Partners LLP bought a new position in shares of China Biologic Products during the 2nd quarter valued at about $842,000. Goldman Sachs Group Inc. raised its holdings in shares of China Biologic Products by 4.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 61,404 shares of the biopharmaceutical company’s stock valued at $6,945,000 after buying an additional 2,845 shares in the last quarter. OxFORD Asset Management LLP lifted its position in China Biologic Products by 1.6% in the 2nd quarter. OxFORD Asset Management LLP now owns 14,748 shares of the biopharmaceutical company’s stock worth $1,668,000 after buying an additional 236 shares during the last quarter. Nordea Investment Management AB lifted its position in China Biologic Products by 26.0% in the 2nd quarter. Nordea Investment Management AB now owns 16,636 shares of the biopharmaceutical company’s stock worth $1,882,000 after buying an additional 3,436 shares during the last quarter. Finally, California Public Employees Retirement System lifted its position in China Biologic Products by 3.1% in the 2nd quarter. California Public Employees Retirement System now owns 29,500 shares of the biopharmaceutical company’s stock worth $3,336,000 after buying an additional 900 shares during the last quarter. Hedge funds and other institutional investors own 72.82% of the company’s stock.

Several analysts have issued reports on CBPO shares. Jefferies Group LLC reaffirmed a “buy” rating on shares of China Biologic Products in a research note on Friday, August 4th. BidaskClub cut shares of China Biologic Products from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Finally, Zacks Investment Research downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Monday, August 7th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $132.00.

Shares of China Biologic Products, Inc. (NASDAQ CBPO) traded down 1.28% during trading on Tuesday, hitting $94.40. The company had a trading volume of 233,258 shares. China Biologic Products, Inc. has a 52 week low of $88.25 and a 52 week high of $126.47. The stock’s 50-day moving average price is $92.49 and its 200 day moving average price is $103.54. The company has a market capitalization of $2.57 billion, a P/E ratio of 24.57 and a beta of 1.75.

China Biologic Products (NASDAQ:CBPO) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.05. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. The business had revenue of $89.28 million during the quarter, compared to analysts’ expectations of $97.33 million. During the same period in the prior year, the business earned $1.26 EPS. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year. On average, equities research analysts forecast that China Biologic Products, Inc. will post $4.96 earnings per share for the current year.

WARNING: “China Biologic Products, Inc. (CBPO) Holdings Maintained by Barings LLC” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/03/china-biologic-products-inc-cbpo-holdings-maintained-by-barings-llc.html.

About China Biologic Products

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Stock Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related stocks with our FREE daily email newsletter.